More specifically, concerning blood pTau217, a marker showing significant promise in AD screening assays, Mielke et al. observed that pTau217 could only moderately predict abnormal entorhinal cortex tau PET (AUC = 0.81) [33]. The gene discussed is MAPT; the disease is Alzheimer disease.